Bacterial Infections and Mycoses Clinical Trial
Official title:
Research on the Diagnostic Application of Metagenomic Sequencing in Clinical Infectious Diseases
Progress in the diagnosis of infectious pathogens depends on the development of effective methods and the discovery of suitable biomarkers. There are several kinds of methods that have been used in diagnosis of various pathogens, such as microscopic examination, culture, serologic diagnosis or molecular approaches, etc. However, these methods have similar limitations, that is, the single detection of reagents. More importantly, physicians seldom consider infections with rare pathogens. Recently developed metagenomic next-generation sequencing (mNGS) has the capability to overcome limitations of traditional diagnostic tests. This new technology could identify all pathogens directly from sample with a single run in a hypothesis-free and culture-independent manner. Studies have shown that mNGS is more sensitive than traditional culture method in clinical conditions such as blood stream, respiratory and general infections. More importantly, due to unbiased sampling, mNGS is theoretically able to identify not only known but also unexpected pathogens or even discovery novel organisms. It should be noted that mNGS also has some limitations such as human genome contamination and possibly environmental microbial contamination. The vast majority of reads in mNGS are derived from human host. This would impede the overall analytical sensitivity of mNGS for pathogen detection. Host depletion methods or targeted sequencing may help to partially mitigate this disadvantage. As mNGS could not, by itself, define whether the detected microbe is the causative pathogen or environmental microorganism, a multidisciplinary discussion by clinicians, microbiologists as well as the lab technicians is required to interpret the result.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01968395 -
Pharmacokinetics of Caspofungin After One Dose in Patients With Liver Failure
|
Phase 4 | |
Terminated |
NCT00511186 -
A Study in Sepsis Patients With Renal Failure
|
Phase 2 | |
Completed |
NCT00509938 -
Safety of a Single Dose of 5 mg of hLF1-11 Given to Autologous Haematopoietic Stem Cell Transplant Recipients
|
Phase 1/Phase 2 | |
Completed |
NCT00229060 -
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
|
Phase 3 | |
Completed |
NCT00210938 -
Doripenem in the Treatment of Complicated Intra-Abdominal Infections
|
Phase 3 | |
Completed |
NCT01781182 -
Infant Antibiotic Resistance and Implications for Therapeutic Decision-making
|
N/A | |
Completed |
NCT02079298 -
Safety of Fluconazole Treatment of Premature and Full-term Newborn Infants
|
Phase 4 | |
Completed |
NCT02155114 -
Iron Homoeostasis in Inflammation
|
N/A |